Novel drugs selectively target pathway important in rheumatoid arthritis

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor beta (FRbeta), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA)...

Read the whole article on

More from